Evidence of Lifestyle Modification in the Management of Hypercholesterolemia

G.S. Mannu¹*, M.J.S. Zaman², A. Gupta⁴, H.U. Rehman⁵ and P.K. Myint¹,⁶

¹Norfolk and Norwich University Hospital, Norfolk, U.K; ²James Paget University Hospital, Great Yarmouth, Norfolk, U.K; ³The George Institute for Global Health, Sydney, Australia; ³Department of Medicine, West Wales Hospital, Carmarthen, Wales, U.K; ⁴Regina Qu’Appelle Health Region, Regina, SK, Canada; ⁵Norwich Research Park Cardiovascular Group, Norwich Medical School, University of East Anglia, Norwich, U.K

Abstract: Background: Coronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide. The growth of ageing populations in developing countries with progressively urbanized lifestyles are major contributors. The key risk factors for CHD such as hypercholesterolemia, diabetes mellitus, and obesity are likely to increase in the future. These risk factors are modifiable through lifestyle.

Objectives: To review current literature on the potential benefit of cholesterol lowering in CHD risk reduction with a particular focus on the evidence of non-pharmacological/lifestyle management of hypercholesterolemia.

Methods: Medline/PubMed systematic search was conducted using a two-tier approach limited to all recent English language papers. Primary search was conducted using key words and phrases and all abstracts were subsequently screened and relevant papers were selected. The next tier of searching was conducted by (1) reviewing the citation lists of the selected papers and (2) by using PubMed weblink for related papers. Over 3600 reports were reviewed.

Results: Target cholesterol levels set out in various guidelines could be achieved by lifestyle changes, including diet, weight reduction, and increased physical activity with the goal of reducing total cholesterol to <200 mg/dL and LDL-C <100mg/dL. Various dietary constituents such as green tea, plant sterols, soy protein have important influences on total cholesterol. Medical intervention should be reserved for those patients who have not reached this goal after 3 months of non-pharmacological approach.

Conclusion: CHD remains as a leading cause of death worldwide and hypercholesterolemia is an important cause of CHD. Non-pharmacological methods provide initial as well as long-term measures to address this issue.

Keywords: Coronary heart disease (CHD), hypercholesterolemia, CVD risk, lifestyle modification.

INTRODUCTION

Globally coronary heart disease (CHD) maintains its position as the foremost cause of worldwide deaths. The global burden of CHD is expected to rise. It kills more than 110,000 people in England alone each year with greater than 275,000 people having a heart attack annually. Moreover, over 1.4 million people endure angina every year [1]. The lifetime risk of CHD by 40 years of age was almost half for men (48.6%) and a third for women (31.7%) according to data obtained in the Framingham Heart Study [2]. CHD is the commonest cause of mortality and morbidity globally [3]. Combined with changes in the demographic profile and progressively urbanized lifestyles, westernization in developing countries will result in large numbers of adults who are potentially vulnerable to CHD [4]. Furthermore, there is a linear relationship between cholesterol and CHD mortality [5], the risk of which is reduced upon lowering serum cholesterol levels [6,7].

Therefore, the primary prevention of cardiovascular disease (CVD) by treating asymptomatic hypercholesterolemia represents an important step in reducing coronary morbidity and mortality [8]. While there have been several reviews on cholesterol modifying treatment in the primary prevention of CHD, the evidence of lifestyle modification in cholesterol management is less well documented systematically. The objective of this systematic review is therefore to accumulate a detailed overview of current literature on risk assessment and lifestyle (non-pharmacological) management of incidental asymptomatic hypercholesterolemia.

RATIONALE FOR MANAGEMENT OF ASYMPTOMATIC HYPERCHOLESTEROLEMIA

Serum cholesterol level is a major risk factor for CHD. A continuous relationship between low density lipoprotein (LDL) cholesterol and CHD risk is evident and is graded over a wide variety of LDL levels ranging from low to elevated [9]. Higher serum levels of total cholesterol (TC) increased the risk of CHD in the Multiple Risk Factor Intervention Trial (MRFIT) [10]. Even in low serum cholesterol level populations it is clear that lower levels of LDL chole-
terol have a direct impact on reduced coronary event rates compared with those patients with relatively elevated serum LDL levels [11]. This is a finding that has been sustained by multiple other studies [5,12,13].

Before considering the impact of lifestyle changes on serum lipids it is first necessary to briefly review the impact of improving lipid profiles on CVD outcomes. A number of pharmacological studies have clearly shown the beneficial results of improved lipid profiles. Although these studies illustrate the results of pharmacological agents and not lifestyle changes, they serve to demonstrate the impact of improving lipid profiles on morbidity and mortality from CVD. These results can be extrapolated for results obtained at set cholesterol levels obtained from lifestyle changes. In hypertensive patients at moderate cardiovascular risk (in the absence of dyslipidemia), a relative risk reduction of 36% in composite primary end points was achieved in the lipid lowering arm of Anglo-Scandinavian Cardiac Outcome Trial (ASCOT-LLA) [14]. There was a reduction of 37% compared with placebo in the incidence of an initial major coronary event, across both sexes upon receiving Lovastatin in the Air Force/ Texas Coronary Atherosclerosis Prevention (AFCAPS/TexCAPS) study [15]. Moreover, on comparing men treated with cholestyramine with men treated with placebo, the former have demonstrated a 19% lower incidence of coronary artery disease according to data obtained in The Lipid Research Clinics Coronary Primary Prevention Trial [8].

There was more than a third reduction (34%) in coronary end point incidence in dyslipidemic men receiving gemfibrozil in the Helsinki Heart Study [16]. A relative risk reduction of almost a third was described in the risk of coronary events with Pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS) [17]. Diabetic patients with normal or near currently accepted target levels with one other cardiovascular risk factor, have obtained significant reductions in cardiovascular events on taking lipid-lowering 10mg Atorvastatin daily in the Collaborative Atorvastatin Diabetes Study (CARDs) primary prevention trial [18].

To further establish the rationale for managing asymptomatic hypercholesterolemia with lifestyle changes it is worth considering the significant secondary prevention trials published in the literature. The first milestone secondary prevention trial on the topic was the Scandinavian Simvastatin Survival Study (4S) trial. This trial showed a markedly reduced morbidity and mortality associated with CVD in patients using medication to lower cholesterol levels [19]. A reduction in CVD with lower TC and LDL-C levels was further established in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial [20].

The Heart Protection Study was the largest of these statin trials and like the 4S trial used Simvastatin to assess outcomes. However, the Heart Protection Study ranged across high risk subjects between both primary and secondary prevention. It demonstrated that all patients using Simvastatin 40mg daily obtained beneficial outcomes no matter their preliminary cholesterol levels [21]. In other words, those patients with lower LDL-C levels obtained similar benefits when compared with patients with elevated LDL-C levels. Higher dose statin, such as Atorvastatin 80mg resulted in a reduction of 22% in primary composite end point and a mean of 2mmol/L LDL-C compared with Atorvastatin 10mg who had a mean of 2.6mmol/L LDL-C. in The Treatment to New Targets trial (TNT) [22].

Statin, Omega 3 fatty acids and dietary modification have been shown to have beneficial outcomes compared to placebo by reducing cardiovascular and overall mortality in lipid intervention studies [23]. There may not be any overt boundary for reduction in LDL-C below which any further cardiovascular benefit cannot be gained. Levels of LDL-C as low as 1.6mmol/L revealed further risk reduction in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE-IT) study [24]. A range of 1.3 to 1.8 mmol/L for LDL-C is suggested by one study with new research showing even patients in their eighth decade obtain benefit from this [25]. Although these benefits on cardiovascular outcomes are based on pharmacological agents acting to improve lipid profiles, they demonstrate the direct impact that modifying lipid profiles have on prognosis. It is via altering lipid profiles that lifestyle changes play such a pivotal role in altering an individual’s risk profile. This article will focus on the important non-pharmacological methods of obtaining similar results on cholesterol levels.

**METHODOLOGY**

A two-step process utilising a Medline/PubMed systematic search was conducted. The initial search was undertaken using elementary phrases including "guidelines for management of hypercholesterolemia", "non-pharmacological management of hypercholesterolemia", "risk factors for hypercholesterolemia", and "management of hypercholesterolemia. Only the most recent literature in the field was required so the time-window for the literature review was restricted to the past 14 years (1998-2012).

The resultant abstracts were analysed and appropriate papers were selected. The secondary search was performed by (1) using the reference lists of the chosen articles and (2) by using PubMed weblink for related articles. The studies were selected if they were in English language and included the appropriate topics and if there were in the English language. The search produced over 3600 published papers on the topic of evaluating and managing primary and secondary hypercholesterolemia. All of the reports regarding the evaluation and non-pharmacological treatment of hypercholesterolaemia were chosen.

**LIFESTYLE MODIFICATION OR NON PHARMACOLOGICAL MANAGEMENT OF HYPERCHOLESTEROLEMIA**

**Lifestyle Modification**

It is necessary to identify those patients at risk of hypercholesterolaemia in order to focus lifestyle modification advice. This is done via a CVD risk assessment and it comprises of two main aspects, namely lipoprotein analysis and other risk factor identification. A summary of the risk factors used in the Adult Treatment Panel III (ATP III) guidelines and their relation to lifestyle changes and medical therapy is shown in (Fig. 1) [26]. The recommended adult lipid profile is summarised in (Fig. 2).
Fig. (1). Illustrating the relationship of risk assessment at 10 years against clinical need for intervention at respective LDL-C levels. The figure demonstrates the relation of lifestyle changes to overall management of cardiovascular risk and drug therapy. Risk assessment at 10 years can be calculated using Framingham risk tables or via the risk assessment tool on the ATP III home website. The ATP II guidelines describe how the approach to hypercholesterolemia should be based upon the LDL-cholesterol (LDL-C) fraction in addition to CHD risk factors. CHD equivalents are medical factors which confer the same level of risk as a past medical history of CHD. The presence of CHD, any of the shown CHD equivalents, of multiple risk factors from the second column equating to a 10yr risk of CHD >20% (as calculated via Framingham risk tables or online ATP III calculation) require early lifestyle changes once LDL-C is ≥2.58 mmol/L. In the absence of CHD or CHD equivalents then a higher threshold of LDL-C ≥3.36 mmol/L for lifestyle measures can be employed. The final column describes the thresholds at which drug therapy is required in addition to lifestyle factors. All LDL levels are in mmol/L. LDL, Low-density Lipoprotein; CHD, Coronary Heart Disease; LDL-C, LDL-cholesterol fraction. Modified from the ATP III guidelines [28].

Fig. (2). Illustrating the adult lipid profile classification. This diagram allows a clinician to rapidly assess the status of a patient’s lipid profile in accordance with the ATP III guidelines. HDL, High-density lipoprotein; LDL, Low-density lipoprotein; TC, Total Cholesterol. Modified from the ATP III guidelines [28].

Once patients at risk of hypercholesterolemia have been identified, their management could be chosen from a range of non-pharmacological options and the exact regimen should be tailored to the individual patient’s lifestyle. Non-pharmacological management of hypercholesterolemia include lifestyle modification such as advising on balanced diet, physical activity, smoking cessation and advice on alcohol consumption, and is the recommended first line of management for patients with total cholesterol of ≥200 mg/dL and an absolute CVD risk of <20%. These lifestyle interventions are aimed at weight control [27], reducing levels of unhealthy fatty acids such as saturated fat [28] and trans fatty acids (TFA) and improving lipid profile [29-31].
Diet

In the Seven Country Study, the authors reported that the significant difference at a set cholesterol level in absolute CHD mortality rates may be due to other factors, such as diet, that are typical for cultures with a low CHD risk [5]. Compared with monosaturated and saturated fat, polyunsaturated fatty acids (PUFA) appeared to have a protective effect with regard to artherosclerosis [32,33]. Numerous studies have looked into the cholesterol lowering effects of dietary intake of plant sterols. However, there is no clear consensus on effectiveness and NICE requires further randomised controlled trials before making guidance on this topic [34]. Recently, a federally mandated evidence-based review in the United States concluded that n-3FAs, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have clear cardioprotective effects, and national and international expert panels and health organizations have begun to call for increased EPA and DHA intakes [35].

It has been reported by Keys and colleagues that dietary change can have effect on lipid profile [36]. Dietary modification with a healthy and balanced diet could bring multiple benefits including directly modifying lipid profile [37]. In people with hypertension, dyslipidaemia or diabetes, nutritionally balanced meals that meet the recommendations of national health organizations could improve multiple risk factors for cardiovascular disease including blood pressure, lipids levels, carbohydrate metabolism and weight [38]. ATP III recommends reduced intake of saturated fats to <7% of total daily calorie intake with reminder of total fats to 25-35% of total energy intake from polyunsaturated and monounsaturated fatty acids [9]. Intake of total cholesterol should be <200 mg/day. European guidelines encourage intake of fruit and vegetable, whole brain cereals, bread, low fat dairy products, oily fish and omega-3 fatty acids [39]. The total fat intake to account for <30% energy intake and saturated fat intake should not exceed a third of total fat intake and total intake of cholesterol should be <300 mg/day [39].

LDL intake has been reported to have adverse effect on LDL, HDL and triglycerides (TG) [33]. TFA are also suggested to be associated with increase in lipoprotein-A and also may increase insulin resistance [40]. Generally, baked foods such as cookies and fried foods are high in TFA and should be avoided. A summary of the recent studies of dietary constituents that may affect the lipid profile and their respective quantitative impact is shown in Table 1, however a more detailed review of the main ‘functional foods’ that have received attention in the literature are summarised below.

Table 1. The Influence of Dietary Elements to Total Cholesterol

| Change in Cholesterol | Red Yeast Rice ¹ | Guggulipid ² | Almond consumption ³ | Garlic ⁴ | Green tea catechins ⁵ | Chitosan ⁶ | Plant Sterols/Stanols ⁷ | Virgin Olive Oil ⁸ | Mediterranean diet ⁹ | Cocoa ¹⁰ | soy protein isoflavones ¹¹ |
|-----------------------|----------------|-------------|----------------------|---------|----------------------|---------|------------------------|------------------|------------------------|--------|------------------------|
| LDL change (mmol/L)   | -1.11 – 1.15   | ↑ 0.17      | ↓ 0.15 mmol/L        | Unaffec | Unaffected           | Unaffec | ↓ 0.35                 | ↓ 0.08           | ↓ 0.09**               | ↓ 0.15 | ↓ 0.21                 |
| HDL (mmol/L)          | Unaffected     | Unaffected  | Unaffected           | Unaffec | Unaffected           | Unaffec | ↓ 0.36                 | ↓ 0.045          | ↓ 0.03                 | Unaffec | ↑ 0.04                 |
| TC (mmol/L)           | 1.04           | Unaffected  | ↓ 0.18 mmol/L        | Unaffec | Unaffected           | Unaffec | ↓ 0.30                 | ↓ 0.1             | ↓ 0.19                 | ↓ 0.15 | ↓ 0.22                 |
| Level of Evidence     | B              | C           | B                    | B       | A                    | A       | A                      | A                | A                      | A      | A                      |

¹= 41 patients were given capsules containing either rice powder placebo vs. 42 patients given 2.4 g red yeast rice daily with serum measurements at 8 and 12 weeks [75]. A further randomized trial involved giving 1800 mg to 31 patients with 12-24week follow up [161]. ²= Data based on a double-blind, randomized, placebo-controlled trial using a parallel design [73]. However conflicting data available from older studies [70, 71] 3= 25 to 168 g/day significantly lowered total cholesterol [92]. However, insufficient body of evidence to promote almond ingestion as a lipid-lowering regime. ⁴= Data from parallel-design randomized clinical trial involving 192 adults [162]. ⁵= Data from meta-analysis from twenty trials GTCS at doses ranging from 145 to 3,000 mg/day taken for 3 to 24 weeks (N=1,415) [163]. ⁶= Data from meta-analysis from Six randomized, placebo-controlled trials of chitosan in hypercholesterolemic patients (n = 416 patients) [164]. ⁷= Data from a systematic review with meta-analysis of 20 studies showing foods enriched with 2.6 g of phytosterols/stanols per day had a significant cholesterol lowering effect [165]. There is no significant difference between plant sterols and stanols in their cholesterol lowering ability [166]. ⁸= Data based on a multicentre randomized, crossover, controlled trial conducted at 6 research centers from 5 European countries. 200 healthy male participants were randomly assigned to 3 sequences of daily administration of 25 mL of 3 olive oils of varying phenolic content at 3 weeks intervals preceded by 2-week washout periods [93] ⁹= decrease in TC linearly dependent on phenol concentration of olive oil consumed. ⁴= Data obtained from Meta-analysis which identified 6 trials, including 2650 individuals [94]. A further meta-analysis included 50 original research studies (35 clinical trials, 2 prospective and 13 cross-sectional), with 534,906 participants [95]. **=widely quoted but statistically not significant. ¹⁰= data obtained from meta-analysis involving eight trials (215 participants). ¹¹= total cholesterol lowered by 0.15(mmol/L), however statistically insignificant at p=0.08 [83].
Fish Oil and Omega-3

In the early 1990’s, it was clear that a fish oil diet had an important impact on serum lipid profile. Harris et al. showed that a fish oil diet halved triglyceride levels [41]. This effect is not restricted to hypertriglyceridaemic individuals [42]. Over the years a number of randomised control trials have shown the beneficial action of fish oils in lowering cholesterol [43-46]. A recent meta-analysis of 47 studies demonstrated an average daily intake of 3.25 g of EPA and/or DHA reduced TG by 0.34 mmol/L (95% CI: -0.41 to -0.27), but did not affect TC, HDL or LDL cholesterol in hyperlipidaemic subjects [47].

These results have been translated into clinical outcomes and fish oil dietary supplementation has shown encouraging cardiovascular results. Epidemiologic studies demonstrate reductions in the incidence of nonfatal myocardial infarction and ischemic stroke [48]. There is variation in the effects of omega oils, however an individual’s responsiveness to fish oil could be attributed to his/her ApoE genotype [49]. Small studies have shown fish oils help to slightly lower blood pressure as well as having anti-arrhythmic properties [50-53]. These findings have been incorporated in to national clinical guidelines. NICE guidelines recommend CVD patients consume at least 7 g of omega 3 fatty acids per week, but did not affect TC, HDL or LDL cholesterol in hyperlipidaemic subjects [47].

These results have been translated into clinical outcomes and fish oil dietary supplementation has shown encouraging cardiovascular results. Epidemiologic studies demonstrate reductions in the incidence of nonfatal myocardial infarction and ischemic stroke [48]. There is variation in the effects of omega oils, however an individual’s responsiveness to fish oil could be attributed to his/her ApoE genotype [49]. Small studies have shown fish oils help to slightly lower blood pressure as well as having anti-arrhythmic properties [50-53]. These findings have been incorporated in to national clinical guidelines. NICE guidelines recommend CVD patients consume at least 7 g of omega 3 fatty acids per week, but did not affect TC, HDL or LDL cholesterol in hyperlipidaemic subjects [47].

Soya

Soya contains phytoestrogens called isoflavones [58]. A recent meta-analysis of 20 parallel-design studies and 23 crossover studies showed a median of 30 g/d of soya protein consumption was associated with a significant improvement in lipoprotein risk factors for CHD [59]. Combining soya foods in conjunction with a prebiotic drinks increased the colonic fermentation and so potentially could increase the hypocholesterolemic effects of soya [60]. Although the isoflavones component of soya does not appear to be the cause of this improvement, it does have other beneficial effects. It has been shown to reduce carotid atherosclerotic burden and improve vascular endothelial function [61].

However, since the chemical structure of isoflavones is similar to oestrogens, it is unclear whether hormonal adverse effects, such as premenopausal breast or gynaecological cancers may be more prevalent with their use [62]. Additionally, although they are advantageous by being low in saturated fats, substituting other proteins for soya has little overall benefit on clinical outcomes and should be considered only as part of a balanced diet [63].

Plant Sterols and Stanols

Plant sterols and stanols are chemically similar in structure to cholesterol but a methyl or ethyl group in their side chains means they are absorbed weakly in the gastrointestinal tract when contrasted with cholesterol. Plant sterols and stanols are thought to inhibit cholesterol absorption and appear to be active in lowering cholesterol [64]. These compounds are most commonly commercially found in margarines and are a source of their cholesterol lowering marketing campaigns. Table 2 illustrates the plant sterol content of common commercially available margarines [65]. When taken between 2 to 2.5 g/day, products enriched with plant stanol/sterol esters may lower plasma LDL cholesterol levels by 10% to 14% without any reported side effects [66]. A further study has shown daily intake can be increased to 9g, further reducing serum LDL-cholesterol concentrations linearly up to 17.4% [67].

There is no significant difference between plant sterols and stanols in their cholesterol lowering ability [68]. Plant sterols and stanols may have a role in patients with borderline normo/hypercholesterolemia [69]. However there is little evidence directly correlating plant sterol or stanol intake with cardiovascular clinical outcomes. Nonetheless their importance in modifying lipid profiles of patients is reflected in their incorporation in the National Cholesterol Education Program (NCEP) ATP III guidelines on lifestyle changes for elevated LDL-C levels [70].

Gugalipid

Gugalipid is derived from the sticky resin of the mukul myrrh tree. It has been used for thousands of years in Indian Ayurvedic medicine to treat a number of ailments. It has received interest in recent years from herbalist and homeopathic professionals with respect to claims it can lower LDL-C levels and slow atherosclerosis. These claims originate from a multicentre clinical trial in India in the late 1980’s showing significant decrease in LDL-cholesterol with the use of Gugga [71]. The active inericians in gugalipid are the stereoisomers E- and Z-gugulsterone which are antagonist ligands for the bile acid receptor farnesoid X receptor (FXR), which in turn is an important regulator of cholesterol homeostasis [72].

Table 2. Illustrating Common Commercially Available Margarines which Contain Plant Sterols

|                     | Flora Pro-active™ Original™ | Promise Activ™ spread | BENECOL™ Light Spread |
|---------------------|-----------------------------|-----------------------|-----------------------|
| Directed daily intake (amount of Plant Sterols) | 2g                          | 2.240g                | 1g                    |
| Daily recommended amount of Plant Sterols       | 1 to 3 gms of plant sterols per day lowers LDL cholesterol by 5-15% [65] |

Regular consumption of 1 to 3 grams of plant sterols per day lowers LDL cholesterol by 5-15%. Consumption should not exceed 3 grams of added sterols a day [65].
It is via this mechanism that gugalipid likely exerts its impact of cholesterol levels [73]. However more recent studies involving gugalipid have failed to replicate these earlier results on lipid profiles with an American double-blind, randomized, placebo-controlled trial actually suggesting it might in fact raise levels of LDL-C [74]. Additionally, skin rash, abdominal discomfort and other adverse outcomes have been described from the use of gugalipid. A recent paper on the topic concluded that its effects on lipid profiles are still not clear [75].

Red Yeast Rice

Red yeast rice has been used in Chinese cooking for many centuries. It derives its name from rice fermented by the red yeast, Monascus purpureus [76]. The active ingredient is a group of HMG CoA reductase inhibitor-like compounds called monacolins. However other extracts such as Xuezhikang, sterols (discussed above), and monounsaturated fatty acids likely contribute. Red yeast rice has been shown to have significant cholesterol lowering properties [77] however issues over standardized manufacturing practices have been limiting factors to wider promotion [78]. The varying preparations are also an issue when comparing studies of the efficacy of red yeast rice [79].

Xuezhikang may be of benefit in dyslipidemic CHD as it has shown clear lipid-regulating effect on a recent meta-analysis of 22 randomized trials and appears safe and effective in reducing cardiovascular events in these patients [80]. A recent multicentre randomised control trial of 5,000 post-myocardial infarction Chinese patients showed that Xuezhi-kang decreased CV, total mortality need for coronary revascularization by almost a third each. It also reduced TC, LDL-C, and raised HDL-C was safe and well tolerated [81]. The tolerability of red yeast rice is generally good. A small study has suggested that at doses of 2,400 mg twice daily, red yeast rice shows a comparable reduction in LDL-C when compared with pravastatin (20 mg twice daily) [82].

Other Cholesterol Altering Dietary Constituents: Green Tea, Garlic, Cocoa and Almonds

Cocoa products are rich sources of flavonoids, and have been shown to reduce blood pressure and the risk of cardio-vascular disease [83]. They can significantly reduce LDL and TC:HDL-C ratio. Several meta-analyses have been conducting showing the beneficial effects of dark chocolate/cocoa products on total and LDL-C [84-88]. Most studies however, have focused on short-term outcomes and longer term data on clinical outcomes is still required [86,87].

The benefits of green tea polyphenols have been widely documented. A recent meta-analysis of 14 studies demonstrated that green tea resulted in significant reductions in serum TC and LDL-C (by 0.06mmol/l), but with no effect on HDL-C. Two recent large prospective studies; the 2006 Ohsaki study [89], and the 2009 Shizuoka elderly cohort [90] both noted reduced all cause and CVD-related mortality due to and due to cardiovascular disease with Green tea consumption.

A small number of meta-analyses have assessed the literature on the effects of garlic on lipid profiles [91-94]. Garlic may modestly reduce TC levels, but has no real impact on LDL lowering or HDL elevation however these meta-analyses are limited by the methodological quality of existing papers on the topic [91,93]. Limited evidence has suggested 25 to 168 g/day of almonds may significantly lowered total cholesterol [95] but insufficient to promote almond ingestion as part of a lipid-lowering regime. Virgin olive oil and a Mediterranean diet have well documented lipid lowering properties [96-98]. The quantitative evidence for these is summarised in Table 1.

Physical Activity

Physical inactivity is a major underlying risk factor for CVD. It is also independent of other risk factors such as obesity and hypertension [99]. Physical activity or physical fitness have been shown to be associated with reduction in the risk of CVD [100]. Regular physical activity reduces VLDL levels, raises the HDL cholesterol, and to a lesser extent, lowers the LDL levels [101]. Other benefits of regular physical activity include lowering of blood pressure [102,103] and reduction in insulin resistance [104]. The recommendations vary but the general consensus view is that at least 30 minutes of moderate intensity physical activity should be encouraged three to four times a week [105].

Studies from the 1970’s showed a dramatic disparity between the lipid profiles of active and sedentary men [106]. Unsurprisingly exercise regimes have greatest impact on an individual’s lipid profile when combined with dietary changes [107]. The general consensus of contemporary research in the field is that amount of exercise plays a far greater impact on serum lipid profiles than the intensity of exercise [108,109]. There is a clearly graded improvement of lipid profile with amount of exercise [110]. The type of exercise has been the focus of some debate, however generally both aerobic exercise and progressive resistance training improve lipid profiles in adults [111-113].

There are significant gender differences on the effect of exercise on cholesterol levels. HDL-C levels increased significantly more in the men who exercised and dieted than in women [114]. The cause of these differences and the underlying mechanism by which exercise exerts its effect on cholesterol levels is incompletely understood. Exercise reduces hepatic lipase activity and increases lipoprotein lipase activity [115]. Peak LDL particle diameter and HDL2-mass increases with exercise and correlates with the changes in lipid composition [116,117]. These changes are equally important across all age ranges [118,119].

Weight Control

Obesity is also recognized as an independent major risk factor for CHD [120]. Weight reduction therapy for overweight or obese patients, will enhance LDL lowering and provide other health benefits including modifying other lipid and non-lipid risk factors [121]. A large study from Finland suggests cardiovascular outcomes in obese children who subsequently lost weight by adulthood and became non-obese were analogous with those who were never obese [107]. Weight loss is currently recommended for individuals
with a body mass index (BMI) \(\geq 30\) kg/m\(^2\) (obese) and in individuals with a BMI 25-29.9 kg/m\(^2\) (overweight) when 2 or more risk factors are present. Waist circumference of >102 cm in men and >88 cm in women is also a risk factor for CHD. A specialist dietician should participate actively in the dietary management of these patients.

**Smoking**

Smoking cessation is possibly the single most significant lifestyle change an individual can make as it is a major modifiable risk factor for CVD [122-125]. It has a synergistic adverse effect in combination with high cholesterol levels. Nicotine replacement therapy is proven as adjunctive therapy to increase the probability of quitting smoking [126]. Bupropion (Zyban) is a selective reuptake inhibitor of Dopamine and Noradrenaline which prevents or reduces cravings and other features of nicotine withdrawal. Bupropion SR is useful oral non-nicotine therapy for smoking cessation [127]. Individual counselling from a smoking cessation specialist is also better than no counselling [128], as are group programmes [129].

Smoking increases TC, and lowers HDL-C and raises LDL-C [130,131]. Initial low cholesterol levels prior to initiating smoking confer no protective benefit against smoking-related atherosclerotic cardiovascular disease [132]. The adverse outcomes on LDL-C and HDL-C are worse in younger smokers between 8- to 19-years-old [131]. Cigarette smoking cessation increases serum levels of HDL-C but not of TC, LDL-C, and TG [133].

**Alcohol Consumption**

The link between alcohol and lipid profiles has been well established for several decades. In the 1960s, hyperlipidaemia across all lipoprotein classes was noted in rats after feeding them with alcohol [134-136]. Since then it has been extensively noted that alcohol significantly increases levels of high density lipoprotein cholesterol and results in favourable changes in several cardiovascular biomarkers in human studies [137,138]

Epidemiological studies are consistent in showing that light to moderate alcohol intake has an inverse association with the risk of cardiovascular disease morbidity and mortality compared with those who do not drink or who consume alcohol in excess amount [139]. Alcohol is thought to reduce the risk of cardiovascular disease through increases in HDL cholesterol and is likely to be of more benefit in combination with a healthier lifestyle such as remaining physically active [140]. The current recommendation set forth by the American Heart Association and other groups is to limit alcohol intake to no more than 2 drinks per day for men and 1 drink per day for women.

Drug therapy should be considered for patients who have failed to attain the goals of lowering the LDL-C <100mg/dL and reducing total cholesterol to <200 mg/dL after 3 months of the above detailed non-pharmaceutical approaches.

**FACTORS AFFECTING COMPLIANCE WITH LIFESTYLE CHANGES**

Despite the extensive literature on the benefits of the above lifestyle changes on lipid profile, there are a number of factors affecting patient compliance with lifestyle advice. Factors contributing to poor compliance after counselling on lifestyle changes are summarised in Table 3. There have been a number of theories to conceptualise the process of lifestyle modification. In relation to lifestyle modification for the treatment of hypercholesterolemia, two main theories are significant and largely overlapping; the transtheoretical model of health behaviour change [141] and the health belief model [142]. Their relationship is summarised in Table 4 [141,142].

Factors affecting cognitive ability such as dementia, brain injury or level of education will directly impact comprehension of the significance of lifestyle changes. Reversible factors affecting cognition such as clinical depression act as barriers in effective lifestyle stage [143]. Poor patient motivation acts as a barrier to the precontemplative stage of potential lifestyle modification and can prove difficult hurdle to pass. The best approach appears to be clear patient communication in a professional healthcare setting [144]. The use of motivational interviewing techniques appears to enhance weight loss in overweight and obese patients [145,146].

**Table 3. Factors Contributing to Poor Compliance After Counselling on Lifestyle Changes**

| Factor                        | Impact on Compliance | Impact on Success Rate |
|-------------------------------|----------------------|------------------------|
| **Patient Factors**           |                      |                        |
| Poor Patient Motivation       | ↓                    | ↓                      |
| Poor Cognition                | ↓                    | ↓                      |
| Inaccurate Health beliefs     | ↓                    | ↓                      |
| (poorly perceived benefits of change) |                |                        |
| **Clinical factors**          |                      |                        |
| Lack of Clinical follow up    | ↓                    | ↓                      |
| Adverse outcomes of regime\(^1\) |                |                        |
| Complexity of regime\(^1\)    | ↓                    | ↓                      |

Note: \(^1\) Regime is defined as any combination of dietary or lifestyle change
Complex dietary advice and intensive change is likely to fail. Adverse outcomes of exercise regimes such as tiredness, musculoskeletal issues, or social embarrassment should be addressed with empathy to improve patients' weight-related attitudes [147]. Patients should be regularly followed up to assess their progress as well as to address any of their queries [148]. Frequent telephone contact with a dietitian was found to be as effective as face-to-face dietitian contact for supporting lifestyle modification in obese patients trying to lose weight [149].

**DISCUSSION**

LDL-C alone is not sufficient to accurately represent the complete atherogenic lipid profile. Evidence from studies including the PROCAM [13] and Strong Heart Study [150] propose that HDL-C levels are in fact the major lipid predictors of CVD risk. However, lowering cholesterol continues to be key to the outcomes of statin treatment on CVD prevention according to the results of ALLHAT-LLA trial [151], whereas the outcome benefits of cholesterol reduction are augmented by greater HDL-C levels.

Even though the underlying risk factors regarding the progression of CHD are identical in both sexes, there are a number of quantitative differences. However, as yet there has not been any formal clinical trial focusing specifically on cholesterol lowering in women. Nonetheless, cholesterol lowering is as beneficial in women as in men according to a recent meta-analysis of new statin trials with clinical endpoints. The major controversy in cholesterol screening is whether to screen young adults. Guidelines exclude many persons 65 years and older as well as men and women younger than 35 and 45 years respectively. They also do not recommend measurement of HDL-C.

Even though it has been widely accepted that atherosclerosis is a process which begins at an early stage, there has not been any scientific data to base clinical decisions on how young a patient should be before treatment is considered. The crux of the matter is whether patients under 20 years old should be routinely tested? Additionally, should treatment be started even earlier for high risk people? Unfortunately these are the questions which still remain unanswered. Further controversy arises on the need for aggressive management of hyperlipidaemia in an elderly population over 65 years of age. The debate arises on the fact that cardiovascular morbidity and mortality in this age group is well recognised in increase with ageing yet there has not been much formal evidence to suggest that lipid reduction in this age group has positive effect on outcomes. However, using the data from the Scandinavian Simvastatin Survival Study (4S) in form of sub-analysis has demonstrated that lowering LDL-C in this elderly subgroup reduced all-cause mortality risk by over a third, which equates to a CHD risk-reduction of 43% [19].

A similar 32% relative risk reduction in patients aged 65-75 years of age was elicited in a sub-analysis of Cholesterol and Recurrent Events Trial (CARE) [152]. Although both the CARE and the 4S studies tackled risk reduction secondary prevention, there is good evidence for its role in primary prevention. The AFCAPS/TexCAPS study was a primary prevention trial and subgroup analysis of this trial described a reduction in the rate of CHD events to those similar in young individuals in women > 62 years of age and men > 57 years of age. The Prospective Study of Pravastatin in the Elderly (PROSPER) study has demonstrated a relative reduction of 15% in the risk of primary end points by treating elderly patients (70-82 years old) with Pravastatin [153].

Patient who are informed as being at ‘high-risk’ are more enthused to make lifestyle changes and will reap more substantial individual benefits from reducing risk factors. This is the advantage of a target high-risk population epidemiological approach to hypercholesterolemia. It provides a cost-effective means to target those who will proportionally suffer greatest CHD morbidity and mortality.

However, it is clear that many more people will suffer strokes and coronary events with near average cholesterol levels by sole virtue of the generically elevated risk within the population in its entirety. As a result, this ‘high risk’ approach cannot target the vast majority of the population who will actually suffer from the disease. A further example is the clear association between hypertension and cerebrovascular disease, however many patients who have suffered a stroke have not had hypertension. It is simply due to the numerically greater numbers of people will suffer from greater numbers of strokes (even though proportionally may be a lower risk than hypertensive patients). If the general population cholesterol levels were not so high then the issue of drug based intervention to large numbers of the high risk population would not be such an issue. A recent Dutch study suggested over 50% of patients in primary care did not have sufficient indication for medication based on the Dutch cardiovascular risk management guidelines.

### Table 4. The Process of Lifestyle Modification for Hypercholesterolaemia Divided into Key Components

| Patient’s Stages of Change | Health Behaviour Model |
|----------------------------|------------------------|
| 1) Precontemplation         | 1) Perceived threat    |
| 2) Contemplation            | 2) Outcome expectations|
| 3) Preparation             | 3) Efficacy expectations|
| 4) Action                  |                        |
| 5) Maintenance             |                        |

*1Based on the transtheoretical model of health behaviour change [139]. 2Based on the health belief model [140]*
A different approach to the prevention of CHD aims to control the determinants of population incidence as a whole [154]. This is termed the ‘population strategy’. The risk associated with many clinical variables [155] is continuous with no evidence of threshold. Such variables are strong, consistent predictors of cardiovascular disease in groups, but are poor predictors of susceptibility in individuals. Plotting the population distributions of five groups with increasing median values of risk reveals that their normal distributions shift rightward. Although a study based on the recent Dutch guideline for cardiovascular risk management suggests over half of primary care patients may have insufficient indication for medication [156], a reduction of 10% in cholesterol levels in the entire population has been predicted to reduce coronary heart disease mortality by 20% [157].

Additionally, Framingham data suggests that a 10 mm Hg lowering of the blood pressure distribution as a whole would correspond to about a 30% reduction in the total attributable mortality [154]. To create an environment in which individual behavioural initiatives can succeed, major shifts in population behaviour through public health policy are necessary. Population-level health promotion through government or non-governmental organisations such as disease-specific charities aims to increase awareness of good health and improve access to it. The North Karelia project in Finland began in 1972 at a time when the country had one of the highest rates of cardiovascular disease in the world. The project targeted principally dietary behaviour to reduce cholesterol levels and led to a decrease in cardiovascular incidence in the region [158]. The project influenced dietary behaviour throughout the country with time, and also led to changes in the food industry with increased production of healthier cooking oils and salt reduction in food products. Thus, tackling a country’s unhealthy diet and unhealthy food production policies should be part of the therapy.

The great variability in absolute mortality rates from coronary heart disease at certain cholesterol levels suggests that different factors, both dietary and non-dietary would possibly contribute to this idea. An example supporting this idea in the South Asian population in the UK who have paradoxically high rates of coronary disease despite relatively low total cholesterol and implies other factors may be at work [159]. It is by virtue of this that a global risk stratification should be conducted incorporating all factors and not just high cholesterol as a single entity. An example of this would be the fact that the initiation of medical treatment will be of little help if the person continues smoking and if blood pressure remains poorly controlled [160]. Statistics recently obtained from Britain between 1998 and 2003 demonstrate the reduction in cholesterol has leveled off as obesity has gradually increased [161].

Hence addressing these non-pharmacological factors globally and especially amongst developing countries with progressively urbanized lifestyles are major priorities. This article has described the components of lifestyle modification towards addressing hypercholesterolemia without pharmacological intervention. The evidence of these therapies are growing, and there is already strong support for the impact of green tea catechins, Plant sterols.stanols cocoa, soy protein isoflavones and a Mediterranean diet in the managemen-tof hypercholesterolemia (Table 1). There is little evidence on whether the beneficial effects on lipid profiles may be multiplied on combining these dietary items. However, a trial of 3 months for lifestyle modification prior to considering pharmacological intervention is warranted by a number of cardiovascular guidelines [162,163].

CONCLUSION

CHD is a leading cause of death in industrialised nations. Hyperlipidaemia with elevated serum LDL-C, total cholesterol and triglycerides is a known major cardiovascular risk factor. HDL-C is protective and low HDL-C is recognized as an independent cardiovascular risk factor. Detection and treatment of elevated cholesterol levels in young adults has the potential to prevent premature CHD as well as CVD. The new Joint British Guidelines recommend that clinicians pay equal attention to apparently healthy individuals who are at risk of going on to develop CVD. Based on data from HPS and CARDS trials it may be sensible to start statin treatment on the basis of global cardiovascular risk assessment instead of simple pre-treatment cholesterol values.

In summary, patients with total cholesterol of ≥200 mg/dL and an absolute CVD risk of <20% should be advised about lifestyle changes, including diet, weight reduction, and increased physical activity with the goal of lowering the LDL-C <100mg/dL and reducing total cholesterol to <200 mg/dL. Drug therapy should be considered for patients who have failed to reach this goal after 3 months of non-pharmacological approach.

Intensive drug treatment should be initiated if there are a number of risk factors bestowing 10-year CVD risk of greater than 20%. Drug therapy should be considered in those patients with LDL-C of 130 mg/dL or more [160]. Patients who warrant intensified therapeutic lifestyle changes and drug treatment include those with diabetes mellitus, dyslipidaemia, hypertension, family history of premature CHD, or a combination of these risk factors, since these patients are at high risk of developing CVD [160]. A patient’s absolute risk of cardiovascular events is more significant than the simple pre-treatment lipid values. The objective of therapy should be to achieve considerable absolute reductions in LDL-C and total for that patient. Patients should be monitored vigilantly for compliance and any adverse side effects.

Take-home Message for the Clinicians

- CHD remains as a leading cause of death worldwide and hypercholesterolemia is an importance cause of CHD.
- Asymptomatic hypercholesterolemia in the presence of other risk factors for CHD may be associated with significant risk for CHD morbidity and mortality.
- Currently recommended guidelines suggest “the lower the better” approach with regard to LDL-C and total cholesterol.
- Target cholesterol levels set out in various guidelines could be achieved by lifestyle changes, including diet, weight reduction, and increased physical activity with
Lifestyle Modification for Hypercholesterolemia

the goal of lowering the LDL-C <100mg/dL and reducing total cholesterol to <200mg/dL. Drug therapy should be considered for patients who have failed to reach this goal after 3 months of non-pharmacological approach.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENTS

Dr. Gurdeep Singh Mannu’s post was funded by the Academy Foundation Programme of the East of England deanship.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENTS

Dr. Gurdeep Singh Mannu’s post was funded by the Academy Foundation Programme of the East of England deanship.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENTS

Dr. Gurdeep Singh Mannu’s post was funded by the Academy Foundation Programme of the East of England deanship.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENTS

Dr. Gurdeep Singh Mannu’s post was funded by the Academy Foundation Programme of the East of England deanship.

REFERENCES

[1] Gibler Wh, Cannon Cp, Blomkalns Al, et al. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation 2005; 111(20): 2699-2710.

[2] Lloyd-Jones Dm, Larson Mg, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353(9147): 89-92.

[3] Duvall Wl, Vorheimeima Da. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004; 17(1): 51-61.

[4] Yusuf S, John Cairns J, Camm J, Fallen El, Gersh Bj. Evidence-Based Cardiology. John Wiley & Sons, Incorporated, 2003: 3-15.

[5] Verschuren Wm, Jacobs Dr, Bloemberg Bp, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274(2): 131-136.

[6] Larosa Je, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81(5): 1721-1733.

[7] Law Mr, Wald Nj, Thompson Gv. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308(6925): 367-372.

[8] Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251(3): 351-364.

[9] Ncep. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.

[10] Stamler J, Wentworth D, Neaton Jd. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256(20): 2823-2828.

[11] Chen Z, Petro R, Collins R, Macmahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303(6797): 276-282.

[12] Wilson Pw, Anderson Km, Castelli Wp. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hyperensive therapy: the Framingham offspring study. Am J Med 1991; 90(1): 11-16.

[13] Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 Suppl A, A2-11.

[14] Sever Ps, Dahlof B, Poulter Nr, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.

[15] Downs Jr, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615-1622.

[16] Manninen V, Elov Mo, Frick Mh, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260(5): 641-651.

[17] Shepherd J, Cobbie Sn, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301-1307.

[18] Colhoun Hm, Betteridge Dj, Durrington Pn, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.

[19] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.

[20] Lipid-Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349-1357.

[21] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.

[22] Larosa Je, Grundy Sm, Waters Dd, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-1435.

[23] Studer M, Briel M, Leinonen B, Glass Tr, Bucher Hc. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165(7): 725-730.

[24] Ray Kk, Cannon Cp, Mccabe Ch, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46(8): 1405-1410.

[25] O'keefe Jh, Jr., Cordain L, Harris Wh, Moe Rm, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43(11): 2142-2146.

[26] Ncep. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-3142.

[27] Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366(9497): 1640-1649.

[28] Nordoy A, Goodnight Sh. Dietary lipids and thrombosis. Relationships to atherosclerosis. Arteriosclerosis 1990; 10(2): 149-163.

[29] Ascherio A, Willett Wc. Health effects of trans fatty acids and hydrogenated vegetable fats: update of a long-term follow-up of the Seven Countries Study. JAMA 1994; 272(13): 1364.

[30] Clifton Pm, Keogh Jb, Noakes M. Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J Nutr 2004; 134(4): 874-879.

[31] Connor Wc, Defrancesco Ca, Connor Sl. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann N Y Acad Sci 1993; 683: 16-34.

[32] Rudel Ll, Parks Jk, Sawyer Jk. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15(12): 2101-2110.

[33] Kris-Etherton P, Daniels Sr, Eckel Rh, et al. Summary of the scientific conference on dietary fatty acids and cardiovascular health:
conference summary from the nutrition committee of the American Heart Association. Circulation 2001; 103(7): 1034-1039.

[34] Nice. Identification and management of familial hypercholesterolemia. National Institute for Health and Clinical Excellence 2008; CG71: 120.

[35] Harris Ws. Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk? Curr Atheroscler Rep 2004; 6(6): 447-452.

[36] Keys a Aj, Grande F. Serum cholesterol response to changes in diet, IV: particular saturated fatty acids in the diet. Metabolism 1965; 14: 776-787.

[37] Km Km, Brand Miller J, Pollicino C, et al. Diets with a lower glycemic load associated with higher HDL-cholesterol in secondary cardiovascular disease. Asia Pac J Clin Nutr 2003; 12(Supply): S22.

[38] Mc Carron Da, Oparil S, Chait A, et al. Nutritional management of cardiovascular risk factors. A randomized clinical trial. Arch Intern Med 1997; 157(2): 169-177.

[39] D W. International Task Force for prevention of coronary heart disease/International Atherosclerosis Society. Coronary Heart Disease. Reducing the risk. Nutr Metab Cardiovascular D 1998; 8: 205-271.

[40] Schaefer Ej. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 2002; 75(2): 191-212.

[41] Harris Ws, Connor We, Illingworth Dr, Rotherock Dw, Foster Dm. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res 1990; 31(9): 1549-1558.

[42] Sullivan Dr, Sanders Ta, Traynor Im, Thompson Gr. Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis 1986; 61(2), 129-134.

[43] Gunnarsdottir I, Tomasson H, Kiyel M, et al. Inclusion of fish or fish oil in weight-loss diets for young adults: effects on blood lipids. Int J Obes (Lond) 2008; 32(7), 1105-1112.

[44] Layne Ks, Goh Yk, Jumpsen Ja, Ryan Ea, Chow P, Clandinin Mt. Normal subjects consuming physiological levels of 18:3(n-3) and 20:5(n-3) from flaxseed or fish oils have characteristic differences in plasma lipid and lipoprotein fatty acid levels. J Nutr 1996; 126(9), 2130-2140.

[45] Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, et al. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol 2009; 64(3): 321-327.

[46] Beil Fu, Terres W, Orgass M, Greten H. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridaemia. Atherosclerosis 1991; 90(1): 95-97.

[47] Eslick Gd, Howe Pr, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009; 136(1): 4-16.

[48] Robinson Jg. Stone Nj. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 2006; 98(4A): 39-49.

[49] Mattar M, Obied O. Fish oil and the management of hypertriglyceridermia. Nutr Health 2009; 20(1): 41-49.

[50] Erkkila At, Schwab Us, De Mello Vd, et al. Effects of fatty and lean fish intake on blood pressure in subjects with coronary heart disease using multiple medications. Eur J Nutr 2008; 47(6): 319-328.

[51] Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of omega-3 fatty acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 2010; 85(2): 122-128.

[52] Zhan S, Ho Se. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 2005; 81(2): 397-408.

[53] Anderson Jw, Bush Hm. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr 2011; 30(2), 79-91.

[54] Wong Jn, Kendall Cw, De Souza R, et al. The effect on the blood lipid profile of soy foods combined with a probiotic: a randomized controlled trial. Metabolism 2010; 59(9): 1331-1340.

[55] Chan Yh, Lau Kk, Yiu Kh, et al. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr 2007; 86(4): 938-945.

[56] Khan Sa, Chatterton Rt, Michel N, et al. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 2012; 5(2): 309-319.

[57] Sacks Fm, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113(7): 1034-1044.

[58] Escurriol V, Cofan M, Serra M, et al. Serum sterol responses to increasing plant sterol intake from natural foods in the Mediterranea ne diet. Eur J Nutr 2009; 48(6), 373-382.

[59] Acnfp. Cholesterol Lowering: Foods with added plant sterols. Cholesterol Lowering: Foods with added plant sterols 2005; 2012/4/7/0/2012.

[60] Plat J, Mensink Rp. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol 2005; 96(1A), 15D-22D.

[61] Mensink Rp, De Jong A, Lyjohann D, Haeren G, Plat J. Plant sterols dose-dependently decrease LDL-cholesterol concentrations, but not cholesterol-standardized fat-soluble antioxidant concentrations, at intakes up to 9 g/d. Am J Clin Nutr 2010; 92(1): 243-313.

[62] Talati R, Sobieraj Dm, Makaji Ss, Phung Oj, Coleman Ci. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. J Am Diet Assoc 2010; 110(5): 719-726.

[63] Doggrell Sa. Lowering LDL cholesterol with margarine containing plant stanol/stere esters: is it still relevant in 2011? Complement Ther Med 2011; 19(1): 37-46.

[64] Grundy Sm. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol 2005; 96(1A): 47D-50D.

[65] Nityanand S, Srivastava Js, Asthana Op. Clinical trials with gugulipid. A new hypolipidemic agent. J Assoc Physicians India 1989; 37(5): 323-328.

[66] Singh Rb, Niaz Ma, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994; 8(4): 659-664.

[67] Uzair Nl, Moore Dd. GUGULIPID: a natural cholesterol-lowering agent. Ann Rev Nutr 2003; 23: 303-313.

[68] Ozanyan A, Diamant C, Kavtsova A, et al. Cholesterol metabolism and hypolipidemic activity of the steroidal ingredient guggulsterone in hyperlipidemic rabbits. Arzneimittelforschung 2003; 53(9): 685-690.

[69] Uzair Nl, Uzair Nl, Moore Dd. GUGULIPID: a natural cholesterol-lowering agent. Ann Rev Nutr 2003; 23: 303-313.

[70] Szapary Po, Wolfe Mi, Bloedon Lt, et al. Gugulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003; 290(6): 765-772.

[71] Ulbricht C, Basch E, Szapary P, et al. Gugulipid for hyperlipidemia: a review by the National Standard Research Collaboration. Complement Ther Med 2005; 13(4), 279-290.

[72] Heber D, Yip I, Ashley Jm, Elashoff Da, Elashoff Rm, Go V. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999; 69(2): 231-236.

[73] Bogsrd Mp, Ose L, Langslet G, et al. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Atherosclerosis 2004; 176(1-2): 217-225.

[74] Klinek M, Wang S, Ogunkanni A. Safety and Efficacy of Red Yeast Rice (Monascus purpureus) as an Alternative Therapy for Hyperlipidemia. P T 2009; 34(6): 313-327.

[75] Gordon Ry, Becker Dj. The role of red yeast rice for the physician. Curr Atheroscler Rep 2011; 13(1): 73-80.

[76] Shang Q, Liu Z, Chen Kx, Xu H, Liu J. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart dis-
ease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012; 636547.

[81] Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101(12): 1690-1693.

[82] Halbert Sc, French B, Gordon Ry, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010; 105(2): 198-204.

[83] Hooper L, Kay C, Abdelhamid A, et al. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr 2012; 95(3): 740-751.

[84] Tokede Oa, Gaziano Jm, Djoussé L. Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. Eur J Clin Nutr 2011; 65(8): 879-886.

[85] Jia L, Liu X, Bai Yy, et al. Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2010; 92(1): 218-225.

[86] Shmirge, Bauer Sr, Medonald Ae, Chowdhury Nh, Collart Ce, Ding El. Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a meta-analysis of short-term studies. J Nutr 2011; 141(11): 1982-1988.

[87] Hooper L, Kroon Pa, Rimm Eb, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008; 88(1): 38-50.

[88] Curtis Pj, Sampson M, Potter J, Dhathariya K, Kroon Pa, Cassidy A. Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year CVD risk in medicated postmenopausal women with type 2 diabetes: a 1-year, double-blind, randomized, controlled trial. Diabetes Care 35(2): 226-232

[89] Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296(10): 1255-1265.

[90] Suzuki E, Yorifuji T, Takao S, et al. Green tea consumption and mortality among Japanese elderly people: the prospective Shizuoka elderly cohort. Ann Epidemiol 2009; 19(10): 732-739.

[91] Reinhart Km, Talati R, White Cm, Coleman Ci. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Rev 2009; 67(1): 39-48.

[92] Khoo Ys, Azie Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 2009; 34(2): 133-145.

[93] Alder R, Lookinland S, Berry Ja, Williams M. A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. J Am Acad Nurse Pract 2003; 15(3): 120-129.

[94] Stevinson C, Pittler Mh, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 2000; 133(6): 420-429.

[95] Phung Oj, Makani Ss, White Cm, Coleman Ci. Almonds have a neutral effect on serum lipid profiles: a meta-analysis of randomized trials. J Am Diet Assoc 2009; 109(5): 865-873.

[96] Covas Mi, Nyssen Kon, Poulsen He, et al. The effect of pheno- nols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med 2006; 145(5): 333-341.

[97] Nordmann A, Suter-Zimmermann K, Bucher H, et al. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 2011; 124(9): 841-851 e842.

[98] Kastorini Cm, Milionis Hj, Esposito K, Giugliano D, Gouveenos Ja, Panagiotakos Db. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011; 57(11): 1299-1313.

[99] Eaton Ch. Relation of physical activity and cardiovascular fitness to coronary heart disease, Part I: A meta-analysis of the independent relation of physical activity and coronary heart disease. J Am Board Fam Pract 1992; 5(1): 31-42.

[100] NIH. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 1996; 276(3): 241-246.

[101] Durstine Jl, Grandjean Pw, Cox Ca, Thompson Pd. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 2002; 22(6): 385-398.

[102] Whelton Sp, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136(7): 493-503.
meta-analysis of 39 controlled trials. JAMA 1988; 259(19): 2883-2889.

[126] Ford C, Zlatek J. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2003; 80(5): 652-656.

[127] Richmond R, Zwar N. Review of bupropion for smoking cessation. Drug Alcohol Rev 2003; 22(2): 203-220.

[128] Lancaster T, Stead Lf. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD001292.

[129] Stead Lf, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD000107.

[130] Nakamura K, Barzi F, Huxley R, et al. Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? Heart 2009; 95(11): 909-916.

[131] Craig Wy, Palomaki Ge, Johnson Am, Haddow Je. Cigarette smoking-associated changes in blood lipid and lipoprotein levels in the 8- to 19-year-old age group: a meta-analysis. Pediatrics 1990; 85(2): 155-158.

[132] Jee Sh, Park J, Jo I, et al. Smoking and atherosclerotic cardiovascular disease in women with lower levels of serum cholesterol. Atherosclerosis 2007; 190(2): 306-312.

[133] Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003; 37(4), 283-290.

[134] Baraona E, Lieber Cs. Fatty liver, hyperlipemia, and erythrocyte alterations produced by ethanol feeding in the rat. Am J Clin Nutr 1969; 22(3), 356-357.

[135] Baraona E, Lieber Cs. Effects of chronic ethanol feeding on serum lipoprotein metabolism in the rat. J Clin Invest 1970; 49(4), 769-778.

[136] Baraona E, Pirola Re, Lieber Cs. Pathogenesis of postprandial hyperlipemia in rats fed ethanol-containing diets. J Clin Invest 1973; 52(2): 296-303.

[137] Brien Se, Ronksley Pe, Turner Bj, Mukamal Kj, Ghali Wa. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 2011; 342: d636.

[138] Ronksley Pe, Brien Se, Turner Bj, Mukamal Kj, Ghali Wa. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342: d671.

[139] Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004; 38(5): 613-619.

[140] Pedersen Jo, Heitmann Bl, Schnohr P, Gronbaek M. The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality. Eur Heart J 2008; 29(2): 204-212.

[141] Prochaska Jo, Velicer Wf. The transtheoretical model of health behavior change. Am J Health Promot 1997; 12(1): 38-48.

[142] Glanz K, Rimer Bk, Viswanath K. Health Behavior and Health Education: Theory, Research, and Practice. John Wiley & Sons, 2008.

[143] Somerset Sm, Graham L, Markwell K. Depression scores predict adherence in a dietary weight loss intervention trial. Clin Nutr 2011; 30(5): 593-599.

[144] Pollak Ki, Alexander Sc, Coffman Cj, et al. Physician communication techniques and weight loss in adults: Project CHAT. Am J Prev Med 2010; 39(4): 321-328.

[145] Armstrong Mj, Mottershead Ta, Ronksley Pe, Sigal Rj, Campbell Ts, Hemmelgarn Br. Motivational interviewing to improve weight loss in overweight and/or obese patients: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2011; 12(9): 709-723.

[146] Pollak Ki, Coffman Cj, Alexander Sc, et al. Predictors of weight loss communication in primary care encounters. Patient Educ Couns 2011; 85(3), e175-182.

[147] Cox Me, Yancy Ws, Jr., Coffman Cj, et al. Effects of counseling techniques on patients’ weight-related attitudes and behaviors in a primary care clinic. Patient Educ Couns 2011; 85(3): 363-368.

[148] Bihan H, Takbou K, Cohen R, et al. Impact of short-duration lifestyle intervention in collaboration with general practitioners in patients with the metabolic syndrome. Diabetes Metab 2009; 35(3): 185-191.

[149] Digieno Ag, Mancuso Jp, Gerber Ra, Dvorak Rv. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med 2009; 150(4): 255-262.

[150] Resnick He, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in non-diabetic american indians: The Strong Heart Study. Diabetes Care 2003; 26(3): 861-867.

[151] Allhat. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LTT). JAMA 2002; 288(23): 2998-3007.

[152] Sacks Fm, Pfeiffer Ma, Moye La, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Reocurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001-1009.

[153] Shepherd J, Blauw Gj, Murphy Mb, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623-1630.

[154] Rose G. Sick individuals and sick populations. 1985. Bull World Health Organ 2001; 79(10): 990-996.

[155] Zaman Mj, Sanders J, Crook Am, et al. Cardiothoracic ratio within the "normal" range independently predicts mortality in patients undergoing coronary angiography. Heart 2007; 93(4): 491-494.

[156] Van Duijn Hj, Belo Jn, Blom Jw, Velberg Id, AssangeEf Wj. Revised guidelines for cardiovascular risk management - time to stop medication? A practice-based intervention study. Br J Gen Pract 2011; 61(587): e347-352.

[157] Jousilahti P, Vartiainen E, Pekkanen J, Tuomilehto J, Sundvall J, Puska P. Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland. Circulation 1998; 97(11): 1087-1094.

[158] Puska P. Nutrition and mortality: the Finnish experience. Acta Cardiol 2000; 55(4): 213-220.

[159] McKeigue Pm, Miller Gj, Marmot Mg. Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol 1989; 42(7): 597-609.

[160] Gupta A, Guyomard V, Zaman Mj, Rehman Hu, MyintPk. Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Adv Ther 2010; 27(6): 348-364.

[161] Spriston K P. Risk factors for cardiovascular disease. Health Survey for England 2003. London: The Stationery Office, vol 2.

[162] Williams B, Poulter Nr, Brown Mj et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary, BMJ 2004; 328(7440): 634-640.

[163] Nice. Lipid modification (CG67). Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2008.

[164] Baker Wl, Tercius A, Anglade M, White CM, Coleman Cl. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab 2009; 55(4): 368-74.

[165] Wu T, Fu J, Yang Y, Zhang L, Han J. The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac J Clin Nutr 2009; 18(2): 179-86.

[166] Talati R, Soberaj DM, Makanji SS, Phang Oj, Coleman Cl. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. J Am Diet Assoc 2010; 110(5): 719-26.